AHRQ Calls for More Validation of Telemedicine’s Effectiveness to Guide Policy Decisions

Dec. 11, 2015
While telehealth has been evaluated in thousands of research studies, there is not enough evidence about how effective it is in order to shape policy decisions, according to a draft report from The Agency for Healthcare Research and Quality (AHRQ).

While telehealth has been evaluated in thousands of research studies, there is not enough evidence about how effective it is in order to shape policy decisions, according to a draft report from The Agency for Healthcare Research and Quality (AHRQ).

AHRQ, which is part of the U.S. Department of Health and Human Services (HHS), released a 52-page draft report to provide a framework and an evidence map of the available research regarding the impact of telehealth on health outcomes and healthcare utilization that can be used to inform policy and practice decisions and guide future work. The report is open for public comment until Jan. 6, 2016 and could guide policymakers in the development of legislation.

The AHRQ study was requested by Senators Bill Nelson (R-Fla.) and John Thune (R-S.D.), who asked for a literature review on the value of telehealth and remote patient monitoring, particularly for the chronically ill, with a focus on expanding access to care and reducing costs. A coalition of stakeholders, including several medical, patient advocacy and industry groups, supported the call for a report in a letter sent to Nelson and Senator Susan Collins (R-Maine).

The request for a review is “rooted in a belief that telehealth has the potential to produce positive benefits, a desire to promote the effective use of telehealth, and motivation to remove barriers to its use,” the AHRQ said in its report.

“Telehealth has been described as having great promise in the sense that it could leverage the $30 billion investment in electronic health records that ONC has made in the last half-decade through the Health Information Technology for Economic and Clinical Health (HITECH) Act. While the potential benefits and possible uses have been extensively enumerated and described (e.g., improving quality, promoting safety, and expanding access) there is also a body of literature that outlines barriers as well as challenges to implementation and widespread adoption of telehealth,” the AHRQ report stated.

AHRQ also noted that a key policy consideration is how telehealth might figure into new service delivery and payment models.

“Carrying out telehealth research under models of value-based care presents an important opportunity for future work, as any intervention or innovation that delivers care in more coordinated and efficient ways could be of great benefit to organizations entering into shared-risk models,” AHRQ noted in the study.

Barriers to telehealth adoption include a lack of evidence-based research, sustainability, lack of provider support, reimbursement, scalability and licensure, the report said.

According to AHRQ, studies have proven the value of telehealth interventions to produce positive results when used in the clinical areas of chronic conditions and behavioral health and when telehealth is used for providing communication and counseling and monitoring or management.

“Although we found that many reviews are not structured or conducted in a way that would support current decisions related to telehealth,” the agency noted in the report.

AHRQ recommends a two-pronged approach to advance telehealth. Additional research is needed is needed in a variety of clinical topics and for different healthcare functions for telehealth, according to the study.

“Finally, there clinical areas and roles for telehealth that do not yet have a sufficient evidence base to support important decisions about practice and policy and in these cases, more primary research is needed rather than more systematic reviews.  We identified triage in urgent/primary care, management of serious pediatric conditions and the integration of behavioral and physical health as three potential topics for more primary research,” AHRQ stated in the study.

In addition, the second approach identified by AHRQ is further research into new organizational and payment models. “Going forward, research should be conducted in emerging models of care, particularly value-based models where use of telehealth may improve the ability to share risk and attain quality and related outcomes. These studies of telehealth should consider combinations of applications of telehealth and outcomes that are important in these new models and evaluate the specific contribution telehealth can make in these contexts,” the report stated.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1